March 15, 2026 by Mohr Marketing
Donβt settle for “intake noise.” Leverage our Compliance Shield protocol to acquire signed plaintiffs with 12+ months of usage and imaging-confirmed Intracranial Meningiomas. The Opportunity: Why Pfizer (MDL 3140) Now? Massive Solvency: Unlike other defendants, Pfizer holds immense liquidity, ensuring the “muscle” to absorb global settlements. Scientific Catalyst: A March 2024 BMJ study revealed a…
Continue reading Build a High-Value Depo-Provera Docket with Verified, Audit-Ready Retainers
March 14, 2026 by Mohr Marketing
Depo-Provera MDL Science-Back Intake: How We Filter for the “5.6x Risk” Cohort The catalyst for the Depo-Provera MDL was a bombshell study published in the British Medical Journal (BMJ) in March 2024. That study didn’t just suggest a link; it identified a specific 5.6-fold increased risk of developing meningiomas for women using the drug for…
Continue reading Depo-Provera MDL – How We Filter for the “5.6x Risk” Cohort
March 13, 2026 by Mohr Marketing
The $3B Liquidity Advantage: Why Depo-Provera is the Strategic Play for 2025-2026 As many mass torts face defendants with thinning capital, the Depo-Provera litigation stands out for its defendant solvency. Pfizer holds massive liquidity, providing the “muscle” to absorb a global settlement without the existential risks seen in other recent litigations. A Mature Docket with…
Continue reading Why Depo-Provera is the Strategic Play for 2025-2026
March 12, 2026 by Mohr Marketing
Beyond “Intake Noise”: Why Precision is the Only Way to Build a Depo-Provera Docket The pharmaceutical liability landscape has shifted with the emergence of MDL 3140 (In re: Depo-Provera Products Liability Litigation). While the numbers are massiveβan estimated 74 million users worldwideβthe legal viability of these cases hinges on a level of medical precision that…
Continue reading Why Precision is the Only Way to Build a Depo-Provera Docket
March 11, 2026 by Mohr Marketing
MDL 3140: Is Your Intake Ready for the Depo-Provera Docket? In an era where some mass tort defendants are thinly capitalized or seeking bankruptcy protection, the Depo-Provera litigation offers a rare strategic advantage: Defendant Solvency. Pfizer, the primary defendant, holds massive liquidity, giving them the “muscle” to absorb a global settlement without existential risk to…
Continue reading Defendant Solvency and the Business Case for MDL 3140
March 10, 2026 by Mohr Marketing
The Precision Mandate: Why Medical Integrity is the Only Path to a Defensible Depo-Provera Docket The pharmaceutical liability landscape shifted significantly with the consolidation of MDL 3140 (In re: Depo-Provera Products Liability Litigation). While the sheer scale of the potential plaintiff poolβestimated at 74 million usersβis a headline-grabber, the true story of this litigation lies…
Continue reading Medical Integrity the Only Path to Defensible Depo-Provera Docket
March 2, 2026 by Mohr Marketing
Mohr Marketing Redefines Motor Vehicle Accident Case Acquisition with Exclusive Police Report Data Strategy and AI-Driven DPPA Compliance ALLENTOWN, PA β Mohr Marketing, LLC, a leader in B2B client acquisition for legal professionals, officially announces the launch of its groundbreaking Police Report-Backed MVA Case Acquisition Program. This innovative strategy leverages direct access to official law…
Continue reading Scalable MVA Case Acquisition: AI-Driven Police Report Strategies